Cumberland Pharmaceuticals (CPIX) Competitors $4.28 -0.08 (-1.83%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CPIX vs. NKTR, ASMB, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRXShould you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry. Cumberland Pharmaceuticals vs. Nektar Therapeutics Assembly Biosciences Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol-Myers Squibb Zoetis Royalty Pharma Nektar Therapeutics (NASDAQ:NKTR) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Is NKTR or CPIX more profitable? Cumberland Pharmaceuticals has a net margin of -29.54% compared to Nektar Therapeutics' net margin of -180.70%. Cumberland Pharmaceuticals' return on equity of -9.50% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nektar Therapeutics-180.70% -173.28% -46.31% Cumberland Pharmaceuticals -29.54%-9.50%-3.19% Do institutionals & insiders have more ownership in NKTR or CPIX? 75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 3.7% of Nektar Therapeutics shares are owned by insiders. Comparatively, 44.8% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, NKTR or CPIX? Nektar Therapeutics has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500. Which has stronger earnings and valuation, NKTR or CPIX? Cumberland Pharmaceuticals has lower revenue, but higher earnings than Nektar Therapeutics. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNektar Therapeutics$98.43M1.25-$276.06M-$0.59-1.12Cumberland Pharmaceuticals$37.87M1.58-$6.28M-$0.47-9.11 Does the media prefer NKTR or CPIX? In the previous week, Nektar Therapeutics had 7 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 7 mentions for Nektar Therapeutics and 0 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 0.93 beat Nektar Therapeutics' score of 0.91 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Nektar Therapeutics Positive Cumberland Pharmaceuticals Positive Does the MarketBeat Community believe in NKTR or CPIX? Nektar Therapeutics received 449 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 70.78% of users gave Nektar Therapeutics an outperform vote while only 41.69% of users gave Cumberland Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNektar TherapeuticsOutperform Votes63770.78% Underperform Votes26329.22% Cumberland PharmaceuticalsOutperform Votes18841.69% Underperform Votes26358.31% Do analysts recommend NKTR or CPIX? Nektar Therapeutics presently has a consensus price target of $4.92, indicating a potential upside of 646.08%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Nektar Therapeutics is more favorable than Cumberland Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nektar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Cumberland Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryNektar Therapeutics beats Cumberland Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Remove Ads Get Cumberland Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPIX vs. The Competition Export to ExcelMetricCumberland PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.78M$6.77B$5.58B$7.92BDividend YieldN/A2.80%5.35%4.04%P/E Ratio-5.567.1123.1218.81Price / Sales1.58205.89369.1988.69Price / Cash8.6165.6738.1634.64Price / Book2.186.146.704.18Net Income-$6.28M$142.11M$3.20B$247.10M7 Day Performance-1.15%-6.09%-4.00%-2.96%1 Month Performance-11.93%-10.87%-0.64%-6.48%1 Year Performance147.40%-12.78%9.09%0.20% Cumberland Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPIXCumberland Pharmaceuticals1.0146 of 5 stars$4.28-1.8%N/A+159.5%$59.78M$37.87M-5.5680NKTRNektar Therapeutics4.3658 of 5 stars$0.86-0.4%$4.92+471.3%-29.5%$160.16M$98.43M-1.02220ASMBAssembly Biosciences3.6959 of 5 stars$11.12+1.0%$35.00+214.7%-27.2%$70.68M$28.52M-1.65100LLYEli Lilly and Company4.8077 of 5 stars$865.94+3.4%$1,009.72+16.6%+5.8%$821.06B$45.04B73.9539,000JNJJohnson & Johnson4.704 of 5 stars$163.43-0.1%$171.33+4.8%-2.9%$393.83B$88.82B24.58152,700Analyst ForecastABBVAbbVie4.5288 of 5 stars$209.25-0.4%$211.45+1.1%+14.0%$369.40B$56.33B87.1950,000Positive NewsMRKMerck & Co., Inc.5 of 5 stars$92.39-0.8%$117.12+26.8%-33.5%$233.39B$64.17B13.7369,000Analyst RevisionPFEPfizer4.9858 of 5 stars$26.13-0.6%$31.92+22.2%-11.5%$148.21B$63.63B18.5383,000BMYBristol-Myers Squibb3.8977 of 5 stars$61.09+0.0%$57.86-5.3%+12.4%$123.98B$48.30B-13.8234,300Short Interest ↑Analyst RevisionPositive NewsZTSZoetis4.6127 of 5 stars$163.22+0.1%$215.90+32.3%-3.1%$73.00B$9.26B29.8414,100Positive NewsRPRXRoyalty Pharma4.8772 of 5 stars$33.75+0.1%$41.60+23.3%+4.2%$19.46B$2.26B23.2880Positive News Remove Ads Related Companies and Tools Related Companies NKTR Alternatives ASMB Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives MRK Alternatives PFE Alternatives BMY Alternatives ZTS Alternatives RPRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CPIX) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cumberland Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cumberland Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CPIX Stock Free CPIX Stock Alerts